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The recognition sequences for substrate cleavage by aspartic protease of HIV-1 are diverse and cleavage specificities are
controlled by complex interactions between at least six amino acids around the cleavage site. We have identified 45
efficiently cleaved peptide substrates of HIV-1 protease (PR) using substrate phage display, an approach that can elucidate
both context-dependent and context-independent preferences at individual subsites of a protease substrate. Many of the
selected peptides were cleaved more efficiently and had lower Km values than physiologically relevant substrates of HIV-1
PR. Therefore, mutations occurring in the cleavage sites of the Gag and Gag-pol polyproteins of HIV-1 could significantly
lower the Km values to better compete against drugs for protease binding while maintaining cleavage rates necessary for viral
replication. The most efficiently cleaved peptide substrate derived from these phage, Ac-GSGIF*LETSL-NH2, was cleaved 60
times more efficiently and had a Km approximately 260 times lower than a nine-amino-acid peptide based on the natural
reverse transcriptase/integrase cleavage site when assayed at pH 5.6, 0.2 M NaCl. The peptide substrates selected served
as frameworks for synthesis of tight binding reduced amide inhibitors of HIV-1 PR. The results show that the most efficiently
cleaved substrates serve as the best templates for synthesis of the tightest binding inhibitors. Thus, defining changes in
substrate preferences for drug-resistant proteases may aid in the development of more efficacious inhibitors. © 2000 Academic
Press
INTRODUCTION
Combination drug therapies have been used success-
fully in the treatment of acquired immune deficiency
syndrome (AIDS) brought on by infection of individuals
with HIV-1. In particular, the use of highly specific inhib-
itors of the viral aspartic protease (PR) in combination
with inhibitors of reverse transcriptase have resulted in
dramatic reduction of virus burden with concomitant re-
duction in symptoms associated with the disease. Un-
fortunately, drug resistance development is still a prob-
lem and there is considerable room for inhibitor refine-
ment and for development of more broad-based
inhibitors less likely to be circumvented by the virus.
Defining the determinants of substrate specificity of
HIV-1 PR is a logical first step in the development of such
broad-based inhibitors.
HIV-1 PR is responsible for processing polyproteins
1 To whom correspondence and reprint requests should be ad-
ressed at Department of Molecular Biology, The Scripps Research
nstitute, MB-14,10550 N. Torrey Pines Road, La Jolla, CA 92037. Fax:
858) 784-2750. E-mail: jelder@scripps.edu.
2 Present address: Corvas International, Inc., 3030 Science Park
Road, San Diego, CA 92121 and Department of Vascular Biology, Torrey
Pines Institute for Molecular Biology, 3550 General Atomics Court, San
Diego, CA 92121.
391that contain the structural proteins (Gag polyprotein) and
the enzymes (Gag/Pol polyprotein) required for virus
structure and replication. The protease recognizes, ap-
proximately, the P4–P39 residues of peptide substrates
via a long cavity in the middle of the protease as ana-
lyzed by biochemical experiments (Moore et al., 1989;
Weber et al., 1989) and crystallographic analysis (Erick-
son et al., 1990; Miller et al., 1989; Swain et al., 1990).
HIV-1 PR cleaves at nine sites in the two polyproteins
and the sequences composing the sites are highly di-
verse. In cases where protease cleavage is context in-
dependent, optimal subsite occupancy can be eluci-
dated by the process of characterizing the cleavage of a
series of peptide substrates in which each individual
residue has been sequentially replaced by a variety of
amino acids. This approach is not ideal for the analysis
of HIV-1 PR substrate specificity, however, because this
enzyme exhibits context-dependent specificity (Griffiths
et al., 1992; Pettit et al., 1991; Ridky et al., 1996; Tozser et
al., 1992, 1997). For example, two distinct classes of
peptide substrates have been defined for retroviral pro-
teases. Type 1 substrates contain aromatic amino acids
at the P1 position and proline at the P19 position. Type 2
substrates contain hydrophobic amino acids at both the
P1 and the P19 positions (Pettit et al., 1991). Other studies
address interactions between amino acids bound in ad-
jacent subsites (Ridky et al., 1996) and general sequence
0042-6822/00 $35.00
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K ETcontext dependence of HIV-1 protease specificity (Tozser
et al., 1997). Studies of derivitized, synthetic peptides
potentially exclude the identification of many efficiently
cleaved substrates by context dependent proteases (Bil-
lich and Winkler, 1991; Dunn et al., 1994; Griffiths et al.,
1992; Polgar et al., 1994; Ridky et al., 1996; Szeltner and
olgar, 1996; Tozser et al., 1991b, 1992). Therefore, we
ave employed substrate phage display technology to
ain more insight into the substrate specificity of HIV-1
R and to identify efficiently cleaved substrates of HIV-1
R to serve as leads for the development of transition
tate analogue inhibitors. Since substrate phage display
xperiments can accomplish the screening of very large
ibraries (.108 independent phage clones) of random-
ized hexamer sequences, this technology is well suited
to identify efficiently cleaved substrates that utilize con-
text-dependent interactions.
The homodimeric HIV-1 PR utilizes an acid–base hy-
drolysis mechanism in which aspartic acids 25 and 259
activate a water to perform a nucleophilic attack on the
amide carbonyl between the P1 and the P19 positions in
arious peptide substrates (Silva et al., 1996). Like most
spartic proteases, the optimal conditions for cleavage
f substrates are low pH, approximately pH 4–5 (Polgar
t al., 1994; Szeltner and Polgar, 1996). Polgar and co-
orkers have shown that changes in pH and salt con-
entration drastically affect the K m and k cat values of
IV-1 PR for selected peptide substrates (Polgar et al.,
994; Szeltner and Polgar, 1996). The physiologically rel-
vant conditions of HIV-1 PR cleavage in vivo remain
ndefined. However, many substrate studies have been
onducted at low pH and/or high salt concentrations
elative to physiological conditions (Billich and Winkler,
991; Tomasselli et al., 1990; Tozser et al., 1991a,b). Data
rom these studies may or may not reflect the activity and
pecificity of HIV-1 PR in vivo.
In the present study, we have screened a peptide
hage display library using HIV-1 PR to select for cleaved
eptide sequences under near physiological conditions,
H 6.7 and 0.2 M NaCl. A semiquantitative dot blot
nalysis (Smith et al., 1995) was used to rank the se-
ected substrates from most efficiently cleaved to least
fficiently cleaved. Peptide substrates were then de-
igned based on the randomized hexamer region of 12
fficiently cleaved phage substrates. The k cat and K m for
cleavage of the soluble peptides by HIV-1 PR were de-
termined at pH 5.6 and 6.7. The primary sequences of 11
substrates determined to be more efficiently cleaved
than phage derived from the MA/CA cleavage site of the
Gag and Gag-Pol polyproteins of HIV-1 were compiled to
generate a consensus for the most efficiently cleaved
substrates. In addition, four inhibitors were made by
conversion of the amide bond to a reduced amide be-
392 BECtween the P1 and the P19 sites in four peptides exhibiting
range of k cat and K m values.RESULTS
Approximately 50 phage were picked from titer plates
fter each round of panning and grown in 2-ml cultures.
ach phage clone was digested with 0.5 mg/ml HIV-1
protease and cleavage was examined using the dot blot
method (Fig. 1B). The randomized hexamer region of
selected clones was then sequenced to determine
amino acid sequences susceptible to proteolytic attack.
A list of the primary sequences of the randomized hex-
amer region phage determined to be cleaved by HIV-1
PR is shown in Table 1.
The purpose of this experiment was to identify phage
cleaved by HIV-1 PR. Only one phage was selected more
than once (3A 35 and 2B 27), indicating that a large
repertoire of susceptible sites are present in the hex-
amer library. Furthermore, none of the selected sites
matched known HIV-1 PR cleavage sites, indicating ei-
ther that the screening was not exhaustive or that the
physiological sites were not optimized for maximal cleav-
age efficiency. Phage were ordered by cleavage effi-
ciency to identify phage that were more efficiently
cleaved than the MA/CA-based control phage. To ac-
complish this task all phage determined to be cleaved in
the first dot blot analysis were screened in another large
dot blot analysis in which decreasing concentrations of
enzyme were used, as described under Materials and
Methods (Fig. 1B). The concentration of phage within
each reaction was well below the K m of the phage sub-
trates (less than nanomolar range), based on titer of
nfective phage. When the concentration of substrate is
uch less than the K m of the substrate, the velocity of an
enzyme catalyzed reaction is directly related to the
k cat/K m of the substrate. By adjusting the starting con-
centration of all substrate phage to approximately the
same level, as determined by the relative intensity of
chemiluminescence, the relative k cat/K m of each sub-
strate could be approximated using dot blot ranking (Fig.
1B).
Although the relative cleavage efficiencies of all phage
were determined, the cleavage sites within the random-
ized hexamer were unknown. Peptides were synthesized
that corresponded to the randomized hexamer and im-
mediate flanking sequences of 12 efficiently cleaved
phage. The k cat and K m values of peptides with sufficient
olubility to conduct kinetic measurements were deter-
ined at the pH used in the phage selections, pH 6.7,
nd additionally at pH 5.6, which is closer to the pH used
n many substrate and inhibitor studies of HIV-1 protease
Table 2). The cleavage sites of all peptides listed in
able 2 were determined by mass spectrometry analysis
f cleaved fragments separated by HPLC. A
0-mer based on the matrix/capsid (MA/CA) site,
c-VSQNY*PIVQN-NH2, was synthesized for comparison
AL.to the selected substrates. However, the MA/CA peptide
was insoluble. Therefore, the k cat and K m values of an
creasin
1.alternative peptide derived from the reverse transcrip-
tase/integrase (RT/IN) cleavage site within the HIV-1
Gag/Pol polyprotein, Ac-IRKIL*FLDG-NH2, were deter-
mined. The RT/IN cleavage site peptide was chosen
because it was determined to be the most efficiently
cleaved peptide of the Gag/Pol polyproteins of HIV-1 in a
FIG. 1. (A) The conditions for each round of phage selection. Enzyme
All reactions were terminated with the HIV-1 PR inhibitor JG-365. The s
concentration to the new enzyme concentration with the ratio of the o
values for phage cleavage by HIV-1 PR. Phage were incubated with in
k cat/K m values relative to a phage derived from the MA/CA site in HIV-
HIV-1 PROTEstudy by Tozser et al. (1991a). The initial peptide sub-
strates were constructed to include the randomized hex-amer sequence and five amino acids on each side of the
randomized hexamer to satisfy the substrate length re-
quirement in case the cleavage site was located near
either end of the randomized region. Because their
cleavage sites were predictable in most cases, peptides
were later constructed as 10-mers. The k cat and K m val-
ions were performed at pH 6.7 in 0.1 M MES and 0.2 M NaCl at 37°C.
cy increase was calculated by multiplying the ratio of the old enzyme
tion of cleavage to the new duration of cleavage. (B) Relative k cat/K m
g concentrations of HIV-1 PR in order to determine their approximate
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the 100s, it means that the sequence was selected from an amplified
K ETcleaved peptide, Ac-GSGIF*LETSL-NH2, was cleaved 60
times more efficiently than the RT/IN-based peptide, Ac-
IRKIL*FLDG-NH2. At pH 6.7, Ac-GSGIF*LETSL-NH2 was
till the most efficiently cleaved peptide substrate, but it
as only 18 times more efficiently cleaved than the RT/IN
eptide.
The frequency of appearance of amino acids at each
osition of the most labile phage substrates was ana-
yzed to investigate the substrate specificity of HIV-1
rotease (Table 3). Table 3 was created from the se-
uences of all of the peptides contained in Table 2, listed
bove the RT/IN and MA/CA peptides, which were de-
ermined by dot blot analysis to be more efficiently
leaved than the control MA/CA phage. The results show
ore variety in the amino acids contained at the P39 and
49 positions relative to the P2–P29 positions.
Four of the substrates listed in Table 2 were converted
nto reduced amide inhibitors, and the Kis of these inhibi-
tors were compared to the relative kcat/Km of the corre-
sponding substrates (Table 4). The reduced amide transi-
tion state analogues of peptides were utilized because they
are readily incorporated into peptides synthesized on solid
support using Boc or Fmoc chemistries, with minimal alter-
ation to the backbone of the peptide. All inhibitors were
determined to be competitive inhibitors (by varying enzyme
concentration using Henderson plots for tight binding in-
hibitors and Dixon plots for all other inhibitors). Peptide 5,
Ac-SGGSGVF*VVNGLVPEF-NH2, is an elongated peptide
ersion of inhibitor 59, Ac-GSGVFC(CH2NH)VVNGL-NH2.
he peptide Ac-GSGVF*VVNGL-NH2 was also made, but
as insoluble at concentrations necessary to determine kcat
and Km values. The extra amino acids at the N- and C-
termini would not be expected to affect the kcat and Km
values of the peptide because they are at least two amino
acids to the N- or C-terminus of amino acids recognized by
the protease (P4–P39) (Erickson et al., 1990; Miller et al.,
989; Moore et al., 1989; Swain et al., 1990; Weber et al.,
989) and are therefore expected to be fully solvent ex-
osed in the enzyme/substrate complex.
The transition state analogue inhibitor based on the most
fficiently cleaved substrate, Ac-GSGIFC(CH2NH)LETSL-
H2, was the tightest binding inhibitor at pH 5.6 (Ki 5 5 nM).
However, at pH 6.7, that inhibitor bound less tightly than the
inhibitor Ac-GSGVFC(CH2NH)VEMPL-NH2. The Kis of all
inhibitors containing Glu at the position equivalent to P29 in
their corresponding substrates decreased at pH 6.7 relative
to pH 5.6. In contrast, the Ki of the inhibitor Ac-
SGVFC(CH2NH)VVNGL-NH2, which contained Val at the
position equivalent to the P29 position of its corresponding
library. s indicates that the cleavage site of the peptide, derived from
the phage, was determined using electrospray mass spectrometry. A
AL.TABLE 1
Primary Sequences of Phage Selected with HIV-1 PR
Number Phage ID
Amino acid sequence
. . . P3 P2 P1 s P19P29P39 . . .
1 2A 42 SGVF / TEERLV
2 2B 8 SGLTM / VQELV
3 2B 27 SGIM s FESNLV
4 3A 13 SGQDF / PMYLV
5 3A 32 SGVM / FQTDLV
6 3A 35 SGIM s FESNLV
7 3A 36 SGSY / VEYQLV
8 3B 7 SGLVA / FANLV
9 3B 8 SGVH / FISRLV
10 3B 11 SGNM / LVYSLV
11 3B 13 SGNSVM / IALV
12 3B 21 SGFIG s VSYLV
13 3B 22 SGVH s VEYTLV
14 3B 23 SGMW / FEAPLV
15 3B 28 SGVF / YSRELV
16 3B 33 SGEMF / FPVLV
17 3B 37 SGAF / MTRGLV
18 4A 1 SGIY / LVENLV
19 4A 2 SGVF s VEMPLV
20 4A 3 SGLF s TEYGLV
21 4A 5 SGLY / YVTELV
22 4A 7 SGTF / QVQLV
23 4A 21 SGWVM / TEALV
24 4A 32 SGIY / YSVSLV
25 4A 130 SGL / MEVSKLV
26 4A 141 SGVF s VETSLV
27 4A 155 SGVY s LATDLV
28 4A 188 SGIM s FQSALV
29 4B 1 SGNY s FVQGLV
30 4B 24 SGVF s VVNGLV
31 4B 26 SGVL / FVSSLV
32 4B 31 SGNY s FVETLV
33 4B 36 SGY LEVSSLV
34 4B 41 SGIF s LETSLV
35 4B 43 SGY / VVVSNLV
36 4B 44 SGNM / VMFGLV
37 4B 146 SGGLNM / PALV
38 4B 159 SGNY s LVTSLV
39 5A 2 SGNF / AAFSLV
40 5B 2 SGFAM / AEALV
41 5B 3 SGVY s HVSTLV
42 5B 11 SGIN / FESGLV
43 5B 25 SGLVL / QEGLV
44 5B 32 SGVM / PTMSLV
45 5B 41 SGAY / LIQGLV
MA/CA SGVSQNY s PIVQLV
Note. The primary sequences of the random hexamer region (bold-
face type) and immediate flanking amino acids (italics) of the gene III
product of phage that were selected using HIV-1 PR, as detected by dot
blot analysis. Sequences are listed in order of first round through fifth
round, although they are not ordered from least efficiently cleaved to
most efficiently cleaved. The phage identified as MA/CA contains a
peptide fragment based on the matrix/capsid cleavage site of the Gag
and Gag/Pol polyproteins of HIV-1. The left-most number indicates the
round of selection, the letter denotes the conditions of selection (Fig.
394 BECslash indicates that the cleavage site was deduced based on con-
firmed cleavage sites.
1
2
3
4
5
7
c
a
d
t ere ac
t ents s
1
d
i
a
R
rsubstrate, did not change (within one standard deviation
error) with respect to pH.
DISCUSSION
One objective of these studies was to investigate the
diversity of sites susceptible to cleavage by HIV-1 PR.
The ultimate goal was to investigate the substrate spec-
ificity of HIV-1 protease as well as to identify optimal
sequences to act as a framework for development of
highly efficacious inhibitors of the protease.
T
Peptide Cleavage at pH
Peptide sequence/cleavage site pH 5
. . . P3 P2 P1 s P19 P29 P39 . . . K m (mM) K cat (s
21)
) GSGIF s LETSL 5 6 1 6.6 6 0.4
) GSGVF s VETSL 6.2 6 0.8 5.8 6 0.3
) SGGSGVY s HVSTLVPEF 580 6 20 18 6 1
) GSGVF s VEMPL 25 6 4 3.9 6 0.2
) SGGSGVF s VVNGLVPEF 600 6 200 18 6 6
6) GSGNY s LVTSL 50 6 9 1.79 6 0.07
) GSGVY s LATDL 180 6 20 5.1 6 0.4
8) SGGSGIM s FESNLVPEF Peptide inso
9) GSGIM s FQSAL Peptide inso
10) GSGNY s FVQGL Peptide inso
11) GSGNY s FVETL Peptide inso
12) IRKIL s FLDG 1300 6 100 28 6 1
13) VSQNY s PIVQN Peptide inso
14) GSGLF s TEYGL 300 6 80 0.65 6 0.05
Note. The peptides are ordered from the most efficiently cleaved pe
onducted in 0.2 M NaCl and 0.1 M MES at 37°C. Amino acid sequence
mino acids (italics) of phage, which were identified to be efficiently cle
erived from the RT/IN and MA/CA cleavage sites, respectively, in the H
he error reported as the standard deviation of the trials. All peptides w
he cleavage site as confirmed by mass spectrometry of cleaved fragm
TABLE 3
Distribution of Amino Acids within the Most Efficiently
Cleaved Substrates
P4 P3 P2 P1 P19 P29 P39 P49
S-11 G-11 V-5 Y-5 F-4 V-5 T-4 S-3
I-3 F-4 V-3 E-4 S-3 T-2
N-3 M-2 L-3 A-1 M-1 G-2
H-1 Q-1 E-1 P-1
N-1 N-1
Q-1 D-1
A-1
Note. The frequency of appearance of the amino acids from the P4
to P49 positions is listed for the 11 substrates that were more efficiently
cleaved than the MA/CA-based phage, as determined by dot blot
analysis (Table 2). The cleavage sites of all substrates were confirmed
by mass spectrometry analysis of fragments from the cleavage of
HIV-1 PROTEpeptide models. Amino acids that occurred three or more times in any
position are displayed in boldface type.
p
aThe most efficiently cleaved peptide, Ac-
GSGIF*LETSL-NH2, had a K m value 260 times lower than
the control RT/IN peptide and a k cat value 4 times lower
than the RT/IN peptide, resulting in a peptide that was
approximately 60 times more efficiently cleaved than the
RT/IN peptide at pH 5.6. However, the cleavage effi-
d pH 6.7 by HIV-1 PR
pH 6.7
cat/K m (mm
21 s21) K m (mM) K cat (s
21) K cat/K m (mm
21 s21)
1.3 6 0.3 60 6 20 12 6 2 0.2 6 0.1
0.9 6 0.2 51 6 7 5.2 6 0.5 0.10 6 0.02
0.031 6 0.003 500 6 100 18 6 3 0.04 6 0.01
0.16 6 0.03 160 6 10 5.2 6 0.2 0.032 6 0.003
0.03 6 0.01 Peptide insoluble at K m
0.036 6 0.008 120 6 20 2.9 6 0.3 0.024 6 0.006
0.028 6 0.005 Peptide insoluble at K m
t K m Peptide insoluble at K m
t K m Peptide insoluble at K m
t K m Peptide insoluble at K m
t K m Peptide insoluble at K m
0.022 6 0.002 830 6 20 10 6 3 0.012 6 0.004
t K m Peptide insoluble at K m
.0027 6 0.0007 920 6 40 0.83 6 0.03 0.00090 6 0.00007
o the least efficiently cleaved peptide at pH 6.7. All experiments were
derived from the random hexamer region (boldface type) and flanking
ased on a dot blot assay. IRKILFLDG and SQNYPIVQ (underlined) were
g/Pol polyprotein. Results are reported as the mean of three trials with
etylated at the N-terminus and amides at the C-terminus. s Indicates
eparated by HPLC.
TABLE 4
K i Values of Reduced Amide Inhibitors Derived from Efficiently
Cleaved Peptides
K i (nM)
pH 5.6 pH 6.7
9)GSGIFC(CH2NH)LETSL 5 6 1 52 6 2
49)GSGVFC(CH2NH)VEMPL 18 6 4 29 6 5
59)GSGVFC(CH2NH)VVNGL 100 6 20 90 6 10
149)GSGLFC(CH2NH)TEYGL 200 6 20 1200 6 200
Note. K i values reported for inhibitors 19 and 49 at pH 5.6 were
etermined by fitting data to the Morrison equation for tight binding
nhibitors (Morrison, 1969) and then converting K iapp values to K i values
using the equation
K iapp 5 K iS 1 1 @S#KmD .
Values for K i reported for 59 and 149 at pH 5.6 and 6.7 and 19 and 49
t pH 6.7 were calculated using Dixon plot analysis (Dixon, 1952).
esults are reported as the mean of three trials with the error
eported as the standard deviation of the trials. All experiments were
395PECIFICITYABLE 2
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K ETciency of substrates varied with pH. At pH 6.7, Ac-
GSGIF*LETSL-NH2 was cleaved only 16 times more effi-
iently than the RT/IN peptide. The difference in the
elative catalytic efficiency of Ac-GSGIF*LETSL-NH2 and
he RT/IN peptide results from a significantly higher K m
value for the peptide at higher pH, while the K m and k cat
values of the RT/IN peptide did not change significantly
with pH. All other substrates determined to be more
efficiently cleaved than the RT/IN peptide had k cat/K m
values between the k cat/K m values of the RT/IN peptide
nd those of Ac-GSGIF*LETSL-NH2 at both pH 5.6 and
H 6.7. The changing range in specificity constant with
H may be due to glutamic acid at the P29 positions of
any of the substrates derived from phage display. Pre-
ious studies have shown that substrates that vary by
ne amino acid at the P29 position, Q to E, vary dramat-
cally in their k cat and K m profiles with respect to pH
(Polgar et al., 1994; Szeltner and Polgar, 1996). At low pH,
the peptides containing glutamic acid at the P29 position
had a much lower K m than the peptides containing glu-
tamine. As the pH of cleavage increased above the
optimal condition of cleavage (pH 4–5), the K m of the
eptide containing glutamic acid became more similar to
he K m of the peptide containing glutamine (Polgar et al.,
994).
None of the phage selected using the screen con-
ained the sequences of any of the natural substrates of
IV-1. In addition, only one phage selected was a dupli-
ate. Based on these observations, there are probably
any more phage that could have been identified from
n exhaustive screen. The substrates selected may not
e optimal because the random insert length was
horter than the active site cleft of HIV-1 PR. However,
he purpose of these studies was to identify a range of
abile sequences and to assess the relative ability of
hose sequences to serve as the basis for inhibitor de-
elopment. The following is a discussion of the amino
cids that were contained in the P4–P49 positions of the
substrates from Table 3.
P4. For all of the substrates that were identified as
more efficiently cleaved than the MA/CA phage, the
cleavage sites were not centered in the random hexamer
region of the phage with respect to the P1 and P19
positions. The cleavage sites of all of these peptides
were shifted one amino acid to the N-terminus of the
randomized hexamer region. A paper by Tozser et al.
(1991b) describes the preference for serine at the P4
position of HIV-1 PR substrates. Peptides containing
serine at the P4 position were shown to be cleaved 2.6
times more efficiently than peptides containing any other
amino acid at the P4 position. The combination of pre-
ferring serine at the P4 position and not preferring
leucine and valine at the P39 and P49 positions, respec-
396 BECtively, is likely to be the reason that all of the substrates
included in this analysis contained serine in the nonva-riant N-terminal flanking arm of the phage fusion peptide
in the P4 position.
P3. As a result of the serine anchoring at the P4
position, the P3 positioned amino acid was almost al-
ways glycine of the fusion peptide, which may or may not
be the most preferred amino acid for the P3 position.
There is a possibility that the efficiency of cleavage of
these substrates could be improved with substitution of
the glycine for other amino acids. A study by Billich and
Winkler (1991) concluded that peptides containing Met,
Thr, Phe, and Tyr at the P3 position, in the context of a
peptide derived from the MA/CA cleavage site, were all
approximately five times more efficiently cleaved than a
substrate containing Gly in the same context.
P2. The P2 position was specific for a very limited set
f amino acids with almost equal representation. A pre-
ious study noted that when Asn is contained in the P2
osition, Pro is preferred in the P19 position (Griffiths et
l., 1992). Interestingly, in this study, three substrates
ore efficiently cleaved than the MA/CA phage con-
ained Asn at the P2 position and either an aromatic or a
ydrophobic residue at the P19 site rather than proline.
Only hydrophobic*hydrophobic sites were contained
n the most efficiently cleaved substrates. Dunn et al.
1994) have concluded that Val is the most preferred
mino acid at the P2 site in the context of
ydrophobic*hydrophobic cleavage sites, followed by, in
rder of decreasing preference, isoleucine, alanine, and
eucine. The only three amino acids contained in the P2
f substrates that were more efficiently cleaved than the
A/CA site were Ile, Val, and Asn.
P1. The P1 position was also specific for a limited set
f amino acids. Phenylalanine and tyrosine are very
imilar in structure, varying by only a hydroxyl group at
he para-position of the benzyl ring. Nine of the 11 most
fficiently cleaved substrates in this study contained Phe
r Tyr at the P1 position. Studies by Dunn et al. (1994)
evealed that hydrophobic*hydrophobic peptides differ-
ng only by exchange of Tyr for Phe at the P1 position had
dentical k cat/K m values.
P19. The P19 position was less selective for structurally
similar amino acids than the P2 or P1 positions. Six
different amino acids were contained within the P19
position with varying sizes and chemical properties. Of
the five most efficiently cleaved substrates, three con-
tained Leu and two contained Val.
P29. The P29 position was also selective for a limited
set of amino acids. Three of the five most efficiently
cleaved substrates contained Glu at the P29 position.
However, when switching pH from 5.6 to 6.7, the k cat/K m
of substrates containing Glu at the P29 position de-
reased as much as ninefold, whereas the k cat/K m of the
T/IN peptide, containing Leu at the P29 position, and
AL.peptide 6, containing Val at the P29 position, decreased
less than twofold at pH 6.7, and the k cat/K m of peptide 3,
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ASE Scontaining Val at the P29 position, increased less than
twofold at pH 6.7.
P39. The P39 position seemed to have a strong prefer-
ence for Thr and Ser, although many other amino acids
were tolerated. Seven of the 11 most efficiently cleaved
substrates contained either Thr or Ser at the P39 position
nd 4 of the 5 most efficiently cleaved substrates con-
ained Thr at the P39 position. Relatively few studies have
een conducted on the P39 position.
P49. The P49 position was most selective for small,
ydrophilic amino acids although many different amino
cid types were tolerated at the P49 positions. Three of
he five most efficiently cleaved substrates contained Ser
t the P49 position.
The variety of amino acids increases from the
-terminus to the C-terminus of peptides within the P4–
49 region of substrates listed in Table 3. The P4 and P3
ositions were part of the phage fusion peptide, which
ust be considered in the analysis of variation of amino
cids. Other studies have shown that the P4 and P3
ositions were tolerant of a variety of amino acids even
hough some were preferred over others (Billich and
inkler, 1991; Tozser et al., 1991a). The variety of amino
cids within the P3 and P4 positions would almost cer-
ainly increase compared to the P2 through P29 positions
if the P3 and P4 positions were not part of the fusion
peptide. Although there were preferences in all positions
within the random hexamer region, the P39 and P49
positions tolerated a larger variety of amino acids than
the P2 through P29 positions.
The following consensus sequence is composed of all
amino acids that were contained in 3 or more of the 11
substrates that were more efficiently cleaved than the
MA/CA phage substrate, S-G-[V, N, I]-[F, Y]*[V, L, F]-[E,
V]-[T, S]-S, from the P4 to P49 positions, respectively.
This analysis may be used to investigate subsite pref-
erences, not taking into account the context dependence
of subsites. However, it is well established that the sub-
site preferences of HIV-1 PR can be dependent on the
amino acids that occupy the other subsites of the pro-
tease (Griffiths et al., 1992; Pettit et al., 1991; Ridky et al.,
1996; Tozser et al., 1992, 1997). One of the benefits of
phage display screening is the ability to select for the
best combinations of amino acids. Therefore, it is inter-
esting to analyze the combinations of amino acids con-
tained within the substrates selected from this screen. Of
the 10 phage selected containing Phe at the P19 position,
6 contain Ser at the P39 position. Ser is not contained in
the P39 position in any other cleaved phage sequence,
except one that contains His at the P19 position. These
results are consistent with the conclusions made by Lee
et al. (1998) that the P1 and P3, and P19 and P39, amino
acids share the same binding pocket in HIV-1 PR and
that the amino acid in one subsite (P1 or P19) affects the
HIV-1 PROTEselection of the optimal amino acid in the other subsite
(P3 or P39). Consequently, HIV-1 PR may prefer Ser at the
(
BP39 position when Phe or another large amino acid is
contained in the P19 position.
Threonine is contained at the P39 position of 4 of the
11 phage substrates that were more efficiently cleaved
than the MA/CA phage. All of these substrates contain
either Val or Leu at the P19 position. The combination of
Thr at P39 and Ser at P49 is contained in three of those
peptides. Peptide 2 is identical to peptide 4 except for the
substitution of Met at P39 for Thr and Pro at P49 for Ser
(Table 2). The substitutions change the K m from 6.2 mM
for peptide 2 to 25 mM for peptide 4, indicating a prefer-
nce for the Thr and Ser substitutions at the P39 and P49
ositions, respectively.
Mutations in HIV-1 that can alter its cleavage sites in
ivo can occur (Doyon et al., 1996, 1998; Mammano et al.,
1998; Zhang et al., 1997). Many of the changes to the Gag
and Gag/Pol cleavage sites under the pressure of pro-
tease inhibitors correspond to amino acids found in the
most efficiently cleaved substrates determined in this
study. Presumably, many of the changes to the process-
ing sites lead to substrates with lower K m values. Sub-
trates complete with inhibitors for the active site of the
rotease. The lower the K m of the substrate, the better
the substrate competes with the inhibitor for the binding
site. HIV-1 does not use the tightest binding or most
efficiently cleaved substrates in its life cycle. If the virus
mutates its cleavage sites to sites with lower K m values,
they should compete better with inhibitors. The following
equation describes the relationship between the IC50 of
an inhibitor and the K m of a substrate it competes
gainst:
IC50 5 K iS1 1 @S#Km D .
As the K m of the substrates decreases, the IC50 of the
nhibitor it competes against increases. In addition, as
he k cat/K m ratios of the substrates change relative to one
another, the temporal order of cleavage of the natural
substrates would be expected to change. The temporal
order of cleavage may be important for proper matura-
tion of virion particles (Pettit et al., 1994). In this study,
peptides that had a variety of K m and k cat values were
ound. The cleavage sites in HIV-1 could theoretically
ecrease with respect to K m to compete with inhibitors,
ut still maintain temporal cleavage order by also low-
ring their k cat values. The K m of the substrates selected
n this screen varied with pH. It will be important to
etermine the physiological pH of cleavage for HIV-1 PR
n order to determine the amount that substrates may be
mproved to compete against inhibitors.
Comparison of the K is of inhibitors to the k cat/K m of
ubstrates confirmed that the most efficiently cleaved
ubstrates produced the best inhibitors, as expected
397PECIFICITYBartlett and Marlowe, 1983; Fersht, 1985; Thompson and
auer, 1979). The K is of the inhibitors decreased as the
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K ETk cat/K m of the corresponding substrates increased at pH
.6. At pH 6.7, Ac-GSGIF*LETSL-NH2 was more efficiently
leaved than Ac-GSGVF*VEMPL-NH2, but the inhibitor
Ac-GSGIFC(CH2NH)LETSL-NH2 did not bind as tightly as
the inhibitor Ac-GSGVFC(CH2NH)VEMPL-NH2. In this
ase the change from peptide bond to reduced amide
ond appeared to change the pH sensitivity of the sub-
trates relative to that of the inhibitors. Both inhibitors
ost affinity when changing pH from 5.6 to 6.7, but the
hange in the affinity of Ac-GSGIFC(CH2NH)LETSL-NH2
was greater. These observations indicate that slight vari-
ations in pH sensitivity can occur when converting from
peptide bond to reduced amide bond.
Three of four inhibitors decreased in binding efficacy
when tested at pH 6.7 rather than pH 5.6. All three of
these pH-sensitive inhibitors contained a glutamic acid
in the P29 position. The K i of inhibitor 59, which did not
ontain a glutamic acid in the P29 position, did not
hange with pH. As mentioned above, substrate studies
ndicate that a substrate with the single change of a
lutamine to a glutamic acid have different pH profiles,
specially with respect to K m (Polgar et al., 1994; Szeltner
and Polgar, 1996). Inhibitors that contain glutamic acid at
the P29 position seem to follow similar trends with re-
spect to the dependency of potency on pH. Although the
reduced amides are useful for identifying leads for inhib-
itors, they are much less potent than other transition
state analogues, such as hydroxyethylene-based inhibi-
tors (approximately 1000-fold more potent in similar scaf-
folds) (Tomasselli et al., 1990). Therefore the inhibitors
described here will serve as starting points for further
refinement with alternate transition state analogues.
For drug design, the optimal affinity of inhibitors may
not be as important as finding potent inhibitors that
inhibit many variant forms of HIV-1 PR. In order to identify
sequences that are recognized by a broad range of
proteases, phage libraries may be cleaved sequentially
with different drug-resistant mutant proteases. These
could then be converted to inhibitors, which may be
effective against those proteases. Alternatively, phage
known to be cleaved by one type of protease can be
used in rank order dot blots with drug-resistant mutants
and other related proteases, such as feline immunode-
ficiency virus protease and simian immunodeficiency
virus protease, to identify substrates that are efficiently
hydrolyzed by a broad range of proteases.
As mentioned previously, the specificity of HIV-1 PR is
context dependent. The screening of a random hexamer
library of peptides allowed for the selection of substrates
composed of combinations of amino acids, which were
optimal for efficient cleavage. The large number of im-
proved substrates selected in this study, particularly
given the limitations of the screen, suggests that HIV-1
has a lot of flexibility to improve cleavage sites to better
398 BECcompete against inhibitors. The pool of substrates gen-
erated has been useful for determination of trends in thespecificity for efficiently cleaved substrates of HIV-1 PR
as well as the generation of inhibitor leads with very little
need for prior knowledge of the specificity of the enzyme.
MATERIALS AND METHODS
Reagents. The HIV-1 PR inhibitor JG-365 was kindly
provided by Stephen Kent of Gryphon Sciences. The
concentration of JG-365 was determined by amino acid
analysis. The HIV-1 PR inhibitor Saquinavir was kindly
provided by Roche. The phage hexapeptide library fTC-
LIB-N6 was constructed as described previously (Smith
et al., 1995) and generously provided by Affymax.
The K91 (F1) strain of Escherichia coli was provided by
teve Cwirla (Affymax). MAb 3-E7, which recognizes the
pitope tag at the N-terminus of the phage gene III
roduct, was purchased from Gramsch Laboratories
Schwabhausen, Germany). Pansorbin cells were pur-
hased from Calbiochem. }-Mouse 2° Ab was pur-
hased from ICN. Circle Grow (CG) medium was pur-
hased from Bio101 (Vista, CA). The MA/CA positive
ontrol phage was constructed by Affymax and contains
he insert that expressed the primary sequence
SQNYPIVQ in place of the random hexamer peptide.
he correct DNA sequence of the MA/CA positive control
hage was verified by DNA sequencing using Amersham
equenase version 2.0 reagents, according to the man-
facturer’s instructions. Fmoc and Boc amino acids were
urchased from Novabiochem.
Enzyme purification. The SF2 construct of HIV-1 PR,
ontaining a Q7K mutation for decreased susceptibility
o autolysis, was produced and partially purified as de-
cribed (Lee et al., 1998). The protease was further pu-
rified using a Vydac C4 column (214TP510) of 5-mm pore
size with dimensions 10 3 250 mm using two Waters 510
pumps, a Waters 486 Tunable Absorbance Detector, a
Waters Automated Gradient Controller, and a Waters 746
Data Module using a gradient of 28–64% actonitrile in
0.1% trifluoroacetic acid over 43 min. The molecular
weight of the HIV-1 PR purified product was verified by a
mass reconstruction based on analysis using a PE
SCIEX APIII Biomolecular Mass Analyzer electrospray
mass spectrometer. Lyophilized HIV-1 PR was dissolved
in 6 M GnHCl, 0.1 NH4OAc, 0.001 M DTT at pH 5.6 to
create a stock solution. The stock solution was diluted
100-fold with the reaction buffers for refolding and anal-
ysis.
Measurement of enzyme concentration. The concen-
tration of functional HIV-1 PR was determined using
active site titration with JG-365 and with Saquinavir (Hen-
derson, 1972; Morrison, 1969). A fluorescent substrate for
HIV-1 PR anthranilic acid-Thr-Ile-norleucine-p-nitrophe-
nylalanine-Gln-Arg-NH2 was synthesized using solid
phase Boc-peptide chemistry and designed by Toth and
AL.Marshall (1990). Fluorimetry was performed on a Jasco
FP-777 spectrofluorometer. Active site titrations were
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at pH 5.6 and at pH 6.7 at 37°C using Saquinavir and
JG-365. Enzyme concentrations were determined to be
the same at each pH.
Phage selection. The selection of peptide substrates
ontained within the gene III protein of phage was orig-
nally reported by Matthews and Wells (1993). An alter-
ative method employing the use of polyvalent fd-phage
as used as described (Smith et al., 1995). The HIV-1 PR
has been determined to recognize approximately seven
amino acids in its active site. However, the primary
determinants of the specificity are the P2–P29 amino
acids (Tozser et al., 1992) while the P4, P3 and P39 sites
are tolerant of a larger variety of amino acids (Billich and
Winkler, 1991; Tozser et al., 1992). Use of libraries with
many amino acids could result in selection of sequences
that are cut in more than one location, which would be
selected over sequences that are cut in only one loca-
tion. Therefore, the hexamer library was used to try and
select for sequences that were cut in only one location.
Infective phage (2 3 1010) were incubated with con-
centrations of HIV-1 PR varying from 0.5 to 5.0 mg/ml for
times varying from 2 h to 10 min in a buffer containing 0.2
M NaCl and 0.1 M MES at pH 6.7 at 37°C. Reactions
were transferred to ice and 1% BSA was added. The
reaction mixture was then incubated with 40 mg of mAb
3-E7 for 30 min at 4°C with rocking. Pansorbin cells (200
ml) were added to the solution and rocked at 4°C for 1 h.
The mixture was spun in a microfuge for 2 min. The
supernatant was recovered and reincubated with 200 ml
of fresh pansorbin cells. After 1 h of rocking at 4°C, the
cells were respun in a microfuge for 2 min. The super-
natant was separated from the beads. A small amount
was used for titration of infective phage, and the rest was
used for amplification of the phage library. The screens
used for selecting protease-sensitive phage are shown
in Fig. 1A.
The first round of phage panning was run under initial
conditions shown in Fig. 1A. Each subsequent round of
panning was run with decreasing amounts of enzyme,
time, or both. The library generated from the conditions
that gave the most cleaved phage for each round, as
determined by dot blot, was amplified in K91 bacteria and
used for the next round of screening. After each round,
phage were titered in K91 cells and individual colonies of
K91 cells that contained phage were picked and grown in
2-ml cultures.
Dot blot analysis. The procedure described below is a
modification of a procedure previously conducted by
Smith et al. (1995). Colonies containing phage were
picked from the plates used to determine the titer of
phage selected after each round. Each colony was
grown in 2 ml of CG medium containing 20 mg/ml tetra-
ycline overnight at 37°C. K91 cells were separated from
HIV-1 PROTEhage by centrifugation. Phage were precipitated by
dding 20% (v/v) of 20% (w/v) PEG 8000/2.5 M NaCl to the
t
csupernatant. Phage were resuspended in 1/10 original
volume of phage and bacteria. Each phage solution was
then used for dot blot analysis. Resuspended phage (10
ml) were added to varying concentrations of enzyme in a
solution of 0.2 M NaCl, 0.1 M MES, at pH 6.7. The phage
were digested with concentrations of HIV-1 protease
varying from 0.5 to 5.0 mg/ml for times varying from 30
min to 1 h. Reactions were blotted on nitrocellulose,
0.45-mm pore size, and washed with phosphate-buffered
aline (PBS). mAb 3-E7 was used as a primary antibody
nd the anti-mouse Ab conjugated to HRP was used as
secondary antibody. The presence of the antibody
pitope contained on the phage was visualized using
mersham ECL Western blotting detection reagents.
oss of the antibody epitope signaled the cleavage of the
examer region of the gene III protein on that particular
hage. By varying the concentration of HIV-1 PR, a rela-
ive order of cleavage efficiency for the different phage
ould be established (see Fig. 1B).
Amplification of libraries. Two-milliliter cultures of K91
F1) cells were grown overnight at 37°C in CG medium
nd then transferred to 50 ml of fresh medium and grown
t 37°C until they reached an OD600 of 0.5–1.0. The K91
ells were then spun at 3500 rpm for 10 min. The super-
atant was discarded and the cells were resuspended in
G medium to 10 times the original concentration. The
oncentrated K91 cells (0.5 ml) were incubated with
hage selected using the phage selection methods de-
cribed above at 37°C for 30 min. The infected cells were
dded to 100 ml of CG medium containing 20 mg/ml
tetracycline in a 1-liter flask. The flask was shaken over-
night at 37°C. The next morning, the culture was spun at
4400 g for 10 min. The supernatant was removed and
hen spun again at 4400 g for 10 min more. Polyethylene
lycol 8000 (20 ml of 20% v/v solution), 2.5 M NaCl was
dded to the supernatant followed by a 30-min incuba-
ion at 37°C. The solution was then spun at 4400 g for 30
in. The supernatant was discarded and the centrifuge
ube was drained for 10 min. The precipitate was resus-
ended in 1 ml of PBS. Samples were taken and used to
erform a titration of infective phage.
Peptide synthesis, purification, and analysis. Peptide
equences were selected, based on nucleotide se-
uences of the random hexamer of phage cleaved by
IV-1 PR. Both Fmoc and Boc solid-phase chemistries
ere used to synthesize selected peptides. Standard
oc synthesis protocols were used for all syntheses,
sing Boc-protected amino acids (Kent et al., 1992). An in
itu neutralization approach to syntheses of peptides,
sing Fmoc-protected amino acids, was used according
o published protocols (Alewood et al., 1997), with the
xception that HOBt and PYBOP replaced HBTU. In ad-
ition, amino acid coupling was performed in N-meth-
lpyrrolidinone instead of dimethylformamide. All pep-
399PECIFICITYides were acetylated at the N-terminal nitrogen and
ontained C-terminal amides. Peptides were purified us-
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peptide was verified using the electrospray mass spec-
trometer as indicated above. The composition and con-
centration of each peptide were determined by amino
acid analysis at The Scripps Research Institute Core
Facility.
Peptide kinetics. Peptides were incubated with 13 nM
HIV-1 PR for times varying from 2 to 30 min. The enzyme
was incubated at 37°C in the same concentration used
for the peptide cleavage kinetics experiments, in order to
test the activity of the HIV-1 PR after long periods of
incubation at 37°C. The activity remained constant after
2 h of incubation at 37°C. Reactions were terminated by
addition of TFA to final concentration of 2%. Terminated
reactions were analyzed using an HP1050 HPLC with a
Vydac 18 column (218TP5015) with a 5-mm pore size and
dimensions of 5 mm 3 150 mm. The peak corresponding
to cleaved product was analyzed for rate of increase. All
peptides were completely cleaved in triplicate in order to
correlate peak area of the product with a concentration
of product. The k cat and K m values for each peptide were
fitted to the Henri–Michaelis–Menten equation using Ka-
leidagraph. All reactions were run in triplicate and the
errors are reported as standard deviations. Analysis of
cleavage products by mass spectrometry after separa-
tion on HPLC revealed the presence of only two cleav-
age products for all peptides tested. The cleavage prod-
ucts corresponded to the expected masses for the cleav-
age products resulting from cleavage at the reported
scissile bond.
Inhibitor synthesis. The peptide portion of inhibitors
was synthesized on Rink amide MBHA resin using Boc
chemistry as described above. The reduced amide bond
was incorporated by addition of four equivalents of
L-Boc-Phe-CHO to the unprotected growing peptide
hain on resin, in 1% acetic acid in DMF (Sasaki and Coy,
987). The mixture was incubated at room temperature
or 1.5 h followed by addition of four equivalents of
aCNBH3 to form the reduced amide (Sasaki and Coy,
1987). The peptide chain was then extended using meth-
ods described above for peptide synthesis. L-Boc-alde-
hydes were purchased from Peninsula Laboratories. Pu-
rification of inhibitors was performed as described for
peptides.
Kinetic analysis of inhibitors. The inhibitors Ac-GSGIFC-
(CH2NH)LETSL-NH2 and Ac-GSGVFC(CH2NH)VEMPL-NH2
were analyzed by fitting data to the Morrison equation
because they were within one order of magnitude of the
concentration of HIV-1 PR used in inhibitor assays. When
the concentration of HIV-1 PR was lowered below 5 nM, the
enzyme lost activity over time. The Kis of all other inhibitors
were determined using Dixon plots.
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